Hypertensive disorders in pregnancy affect 1 in 7 hospital deliveries

Translate to Spanish or other 102 languages!

The prevalence of hypertensive disorders in pregnancy (HDP) among delivery hospitalizations increased from about 13% in 2017 to 16% in 2019, affecting at least 1 in 7 delivery hospitalizations during this period, according to a CDC report. Image for illustration purposes
The prevalence of hypertensive disorders in pregnancy (HDP) among delivery hospitalizations increased from about 13% in 2017 to 16% in 2019, affecting at least 1 in 7 delivery hospitalizations during this period, according to a CDC report. Image for illustration purposes

Mega Doctor News

- Advertisement -

CDC – The prevalence of hypertensive disorders in pregnancy (HDP) among delivery hospitalizations increased from about 13% in 2017 to 16% in 2019, affecting at least 1 in 7 delivery hospitalizations during this period, according to a CDC report. About a third of those who died during hospital delivery had a hypertensive disorder of pregnancy documented.

HDP are common and can cause severe complications for pregnant people, such as heart attacks and strokes, and are a leading cause of pregnancy-related death in the United States. It includes both pregnancy-associated hypertension that begins during or after pregnancy, and chronic hypertension that begins before pregnancy and continues during pregnancy.

“There are many strategies that clinicians can use to identify, monitor, and manage people with hypertensive disorders in pregnancy to prevent severe complications and deaths. A great example is home-monitoring of blood pressure during and following pregnancy,” said Janet Wright, M.D., F.A.C.C., director of CDC’s Division of Heart Disease and Stroke Prevention at the National Center for Chronic Disease Prevention and Health Promotion. “At a systems level, intentional programming like Perinatal Quality Collaboratives can improve the quality of care and health outcomes and translate findings into interventions.”

- Advertisement -

Characteristics associated with increased risk for HDP, such as advanced maternal age, obesity, and diabetes have increased in the U.S. and may explain the increase in HDP prevalence.

Racial and ethnic disparities of HDP among hospital deliveries are stark, with HDP affecting more than 1 in 5 delivery hospitalizations of Black women and about 1 in 6 delivery hospitalizations of American Indian and Alaska Native women. Factors contributing to racial and ethnic inequities in HDP include differences in access to and quality of health care, and higher prevalence of characteristics associated with increased risk like obesity. Racial bias in the U.S. healthcare system can affect HDP care from screening and diagnosis to treatment. Psychosocial stress from experiencing racism has also been found to be associated with chronic hypertension.

“As healthcare professionals, we must recognize the factors that contribute to racial inequities and work individually and collectively to reduce these rates.” said Wanda Barfield, M.D., M.P.H., director of CDC’s Division of Reproductive Health at the National Center for Chronic Disease Prevention and Health Promotion. “Addressing hypertensive disorders in pregnancy is a key strategy in reducing inequities in pregnancy-related mortality.”

The highest prevalence of HDP was among delivery hospitalizations of women over the age of 45 (31%).  HDP was also high among people who reside in rural counties (16%), reside in lower income ZIP codes (16%), and delivered in hospitals in the South (16%) or Midwest (15%).

- Advertisement -

Disparities based on location might be due to differences in the prevalence of characteristics associated with increased risk of HDP, including diet, tobacco use, physical activity patterns, experiencing poverty, or access to care. Strengthening regional networks of health care facilities providing risk-appropriate maternal care through telemedicine and transferring people with high-risk conditions to facilities that can provide specialty services are strategies to reduce these disparities.

Severe complications and deaths from HDP are preventable with equitable implementation of public health and clinical strategies. These include efforts across the life course for preventing HDP; identifying, monitoring, and appropriately treating those with HDP with continuous and coordinated care; increasing awareness of urgent maternal warning signs; and implementing quality improvement initiatives to address severe hypertension.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Robotic Surgery Program Expanded at STHS McAllen

From smaller incisions and less pain to shorter hospital stays and faster recovery times, robotic-assisted surgery is changing the way patients experience surgical care.

Texas Oncology to Host Breast Cancer Awareness Symposium in McAllen. FULL TO CAPACITY. NO MORE ROOM.

The Breast Cancer Awareness Symposium 2026 is an educational and networking event hosted by Texas Oncology and sponsored by Caris Life Sciences, bringing together oncology specialists, surgeons, advanced practice providers, and community healthcare professionals to discuss the latest advances in breast cancer prevention, diagnosis, treatment, survivorship, and reconstruction. The symposium's theme, "Breast Cancer 2026: Early Detection, Modern Care, and Survivorship Through Community Partnership," highlights the importance of multidisciplinary collaboration and patient-centered care

Highway Crash Leads to Unexpected STC Connection

What began as a flat tire on the side of a highway turned into a frightening collision and an unexpected encounter for South Texas College faculty member Jesus Amaya, when the paramedic who responded to the scene turned out to be one of STC’s graduates.

FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR.
- Advertisement -